Biogen Plans $34 Million Charge Impacting Q1 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BIIB?
Source: Fool
- Stock Market Decline: Biogen's stock fell nearly 3% on Monday after the company announced plans to book a $34 million charge in Q1, indicating investor concerns about its financial health.
- Expense Breakdown: The charge consists of in-process R&D costs and milestone payments, expected to reduce net income by approximately $0.19 per share, directly impacting investor confidence.
- Earnings Release Schedule: Biogen has scheduled its Q1 earnings report for April 29 before market open, with initial expectations of a slight year-over-year gain to $2.95 per share now at risk due to the newly announced charge.
- Acquisition Activity: Recently, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, which has also unsettled investors; however, the company is pivoting from its traditional focus on multiple sclerosis therapies to higher-potential market segments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 177.340
Low
143.00
Averages
204.45
High
246.00
Current: 177.340
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Plans $34 Million Charge Impacting Q1 Earnings
- Stock Market Decline: Biogen's stock fell nearly 3% on Monday after the company announced plans to book a $34 million charge in Q1, indicating investor concerns about its financial health.
- Expense Breakdown: The charge consists of in-process R&D costs and milestone payments, expected to reduce net income by approximately $0.19 per share, directly impacting investor confidence.
- Earnings Release Schedule: Biogen has scheduled its Q1 earnings report for April 29 before market open, with initial expectations of a slight year-over-year gain to $2.95 per share now at risk due to the newly announced charge.
- Acquisition Activity: Recently, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, which has also unsettled investors; however, the company is pivoting from its traditional focus on multiple sclerosis therapies to higher-potential market segments.
See More
Biogen Plans to Book $34 Million Charge in Q1
- Charge Impact: Biogen plans to book a $34 million charge in Q1, which will directly affect its net income, with an expected loss of approximately $0.19 per share, indicating increased spending on R&D and milestone payments.
- Market Reaction: Following this announcement, Biogen's stock fell nearly 3%, reflecting investor concerns about the company's future profitability, especially as it faces pressure to pivot from its traditional multiple sclerosis therapies.
- Earnings Release Schedule: Biogen has scheduled its earnings report for April 29 before market open, with investors initially expecting a slight year-over-year increase in net income to $2.95 per share, but the $34 million charge may alter these expectations.
- Acquisition Activity: In recent weeks, Biogen announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which, despite failing to boost stock prices, demonstrates the company's commitment to transitioning into higher-potential segments.
See More
Market Capitalization Analysis of American Water Works
- Market Cap Comparison: American Water Works (AWK) has a market capitalization of $26.98 billion, compared to Biogen Inc (BIIB) at $26.03 billion, indicating AWK's relative strength in the market, which may attract more attention from large funds.
- Investor Misconceptions: Many novice investors often mistakenly compare company values solely based on stock prices, but market capitalization provides a more accurate assessment of a company's value, avoiding misunderstandings caused by price differences.
- Market Positioning Impact: Market cap not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to invest in the stock, particularly as large-cap funds tend to focus on companies valued over $10 billion.
- Stock Price Fluctuations: At Monday's close, AWK's stock fell about 0.2%, while BIIB dropped approximately 2.8%, reflecting differing market reactions to these companies, which could influence investor decisions.
See More
Biogen Expects Q1 EPS Impact of $0.19 Due to R&D Charges
- EPS Guidance Adjustment: Biogen anticipates a Q1 GAAP and non-GAAP net income impact of approximately $0.19 per share, primarily due to increased R&D expenses, reflecting ongoing investment pressures in innovation.
- R&D Expense Breakdown: The charge consists of about $34 million in upfront and milestone expenses, pre-tax, indicating Biogen's high investment in new drug development, which may affect profitability in the short term.
- Earnings Report Schedule: The company is expected to release its Q1 earnings report on April 30, with consensus EPS estimates at $3.03 and revenue around $2.25 billion, highlighting investor focus on future performance.
- Market Reaction Analysis: Despite facing short-term profitability pressures, Biogen's recent acquisition of Apellis may yield synergies, and market reactions to this strategic move will influence the company's stock price trajectory.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Biogen's $5.6 Billion Acquisition of Apellis Pharmaceuticals Fails to Boost Stock Price
- Acquisition Overview: Biogen announced its agreement to acquire Apellis Pharmaceuticals for $41 per share in cash, totaling approximately $5.6 billion; however, despite a nearly 3% rise in the broader market, Biogen's stock fell over 2%, indicating investor skepticism about the deal.
- Drug Portfolio Insight: Apellis has two FDA-approved treatments, including Syfovre for age-related macular degeneration (AMD) and Empaveli for rare diseases, and Biogen's acquisition aims to enhance its portfolio in immunology and rare diseases, which are critical growth areas.
- Market Reaction Analysis: Although Biogen's CEO stated that the acquisition would bolster the company's growth potential, investor sentiment appears cautious, leading to a decline in stock price even as the market rallied, reflecting doubts about the deal's immediate value.
- Strategic Transformation: Biogen is transitioning from its previous focus on multiple sclerosis to emerging therapeutic areas like Alzheimer's and postpartum depression, and this acquisition underscores its commitment to future growth, despite the negative short-term market reaction.
See More
Biogen Plans $34 Million Charge Impacting Q1 Earnings
- Stock Market Decline: Biogen's stock fell nearly 3% on Monday after the company announced plans to book a $34 million charge in Q1, indicating investor concerns about its financial health.
- Expense Breakdown: The charge consists of in-process R&D costs and milestone payments, expected to reduce net income by approximately $0.19 per share, directly impacting investor confidence.
- Earnings Release Schedule: Biogen has scheduled its Q1 earnings report for April 29 before market open, with initial expectations of a slight year-over-year gain to $2.95 per share now at risk due to the newly announced charge.
- Acquisition Activity: Recently, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, which has also unsettled investors; however, the company is pivoting from its traditional focus on multiple sclerosis therapies to higher-potential market segments.
See More
Biogen Plans to Book $34 Million Charge in Q1
- Charge Impact: Biogen plans to book a $34 million charge in Q1, which will directly affect its net income, with an expected loss of approximately $0.19 per share, indicating increased spending on R&D and milestone payments.
- Market Reaction: Following this announcement, Biogen's stock fell nearly 3%, reflecting investor concerns about the company's future profitability, especially as it faces pressure to pivot from its traditional multiple sclerosis therapies.
- Earnings Release Schedule: Biogen has scheduled its earnings report for April 29 before market open, with investors initially expecting a slight year-over-year increase in net income to $2.95 per share, but the $34 million charge may alter these expectations.
- Acquisition Activity: In recent weeks, Biogen announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which, despite failing to boost stock prices, demonstrates the company's commitment to transitioning into higher-potential segments.
See More
Market Capitalization Analysis of American Water Works
- Market Cap Comparison: American Water Works (AWK) has a market capitalization of $26.98 billion, compared to Biogen Inc (BIIB) at $26.03 billion, indicating AWK's relative strength in the market, which may attract more attention from large funds.
- Investor Misconceptions: Many novice investors often mistakenly compare company values solely based on stock prices, but market capitalization provides a more accurate assessment of a company's value, avoiding misunderstandings caused by price differences.
- Market Positioning Impact: Market cap not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to invest in the stock, particularly as large-cap funds tend to focus on companies valued over $10 billion.
- Stock Price Fluctuations: At Monday's close, AWK's stock fell about 0.2%, while BIIB dropped approximately 2.8%, reflecting differing market reactions to these companies, which could influence investor decisions.
See More
Biogen Expects Q1 EPS Impact of $0.19 Due to R&D Charges
- EPS Guidance Adjustment: Biogen anticipates a Q1 GAAP and non-GAAP net income impact of approximately $0.19 per share, primarily due to increased R&D expenses, reflecting ongoing investment pressures in innovation.
- R&D Expense Breakdown: The charge consists of about $34 million in upfront and milestone expenses, pre-tax, indicating Biogen's high investment in new drug development, which may affect profitability in the short term.
- Earnings Report Schedule: The company is expected to release its Q1 earnings report on April 30, with consensus EPS estimates at $3.03 and revenue around $2.25 billion, highlighting investor focus on future performance.
- Market Reaction Analysis: Despite facing short-term profitability pressures, Biogen's recent acquisition of Apellis may yield synergies, and market reactions to this strategic move will influence the company's stock price trajectory.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Biogen's $5.6 Billion Acquisition of Apellis Pharmaceuticals Fails to Boost Stock Price
- Acquisition Overview: Biogen announced its agreement to acquire Apellis Pharmaceuticals for $41 per share in cash, totaling approximately $5.6 billion; however, despite a nearly 3% rise in the broader market, Biogen's stock fell over 2%, indicating investor skepticism about the deal.
- Drug Portfolio Insight: Apellis has two FDA-approved treatments, including Syfovre for age-related macular degeneration (AMD) and Empaveli for rare diseases, and Biogen's acquisition aims to enhance its portfolio in immunology and rare diseases, which are critical growth areas.
- Market Reaction Analysis: Although Biogen's CEO stated that the acquisition would bolster the company's growth potential, investor sentiment appears cautious, leading to a decline in stock price even as the market rallied, reflecting doubts about the deal's immediate value.
- Strategic Transformation: Biogen is transitioning from its previous focus on multiple sclerosis to emerging therapeutic areas like Alzheimer's and postpartum depression, and this acquisition underscores its commitment to future growth, despite the negative short-term market reaction.
See More
